Skip to content
RDL
Network
Ecosystem
Switch app
TR
About
FAQ
Sign in
Get started
Thyroid Hormone Nanotherapy Improves Kidney Function and Structure in Diabetic Nephropathy — Angelo Michele Lavecchia (2025) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Thyroid Hormone Nanotherapy Improves Kidney Function and Structure in Diabetic Nephropathy
Shared by
Giuseppe Remuzzi
Thyroid Hormone Nanotherapy Improves Kidney Function and Structure in Diabetic Nephropathy
Article
2025
en
Authors
+5 more
AL
Angelo Michele Lavecchia
IM
Iordanis Mourouzis
DS
Dimitrios Skourtis
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2023
Thyroid hormone treatment counteracts pathological alterations in diabetic nephropathy and diabetic cardiomyopathy
Lavecchia Angelo Michele
,
Polyxeni Mantzouratou
,
Domenico Cerullo
,
Monica Locatelli
,
Sara Conti
,
Matteo Tironi
,
Fabio Sangalli
,
Daniela Corna
,
Carla Zoja
,
Giuseppe Remuzzi
,
Christodoulos Xinaris
Article
2023
Thyroid hormone treatment counteracts cellular phenotypical remodeling in diabetic organs
Angelo Michele Lavecchia
,
Polyxeni Mantzouratou
,
Domenico Cerullo
,
Monica Locatelli
,
Sara Conti
,
Matteo Tironi
,
Fabio Sangalli
,
Daniela Corna
,
Carla Zoja
,
Giuseppe Remuzzi
,
Christodoulos Xinaris
Article
2007
Thyroid hormone attenuates cardiac remodeling and improves haemodynamics early after myocardial infarction
Iordanis Mourouzis
,
Konstantinos Markakis
,
Meletios A Dimopoulos
,
Christodoulos Xinaris
,
Matthew Panagiotou
,
Costas Pantos
,
Dennis V. Cokkinos
Article
2023
Thyroid hormone signalling regulates beta-cell pathological growth, dedifferentiation and transdifferentiation in diabetic pancreas
Lavecchia Angelo Michele
,
Polyxeni Mantzouratou
,
Domenico Cerullo
,
Fabio Sangalli
,
Daniela Corna
,
Carla Zoja
,
Giuseppe Remuzzi
,
Christodoulos Xinaris
Article
2004
Losartan in diabetic nephropathy
Norberto Perico
,
Piero Ruggenenti
,
Giuseppe Remuzzi
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.